NVAX Q4 2022 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$288M+139.6% YoY

Gross Profit

$106M36.8% margin

Operating Income

-$244M-84.7% margin

Net Income

-$182M-63.3% margin

EPS (Diluted)

$-2.28

QoQ Revenue Growth

-60.8%

Cash Flow

Operating Cash Flow

-$118M

Free Cash Flow

-$140M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$2.9B

Stockholders' Equity

-$634M

Cash & Equivalents

$1.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$288M	-$727M	+139.6%
Gross Profit	$106M	-$727M	+114.6%
Operating Income	-$244M	-$825M	+70.4%
Net Income	-$182M	-$846M	+78.5%

Revenue Segments

Product

$288M81%

Grant

$70M19%

Royalties and Other

$39,0000%